Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval

Galderma Laboratories L.P.'s pending launch of Differin Gel 0.1% could push parent firm Nestle SA to the top of the OTC acne treatment market following the Swiss firm's recent investment in a joint venture that will market the current category leader, Proactiv.

While FDA notes continuing concern about the safety for pregnant women's use of adapalene, Differin Gel's active ingredient, and other retinoid class topicals, consultants who worked with Galderma Labs on the Rx-to-OTC switch application say the first-in-class